Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Sant P Chawla; Brian A Van Tine; Seth M Pollack; Kristen N Ganjoo; Anthony D Elias; Richard F Riedel; Steven Attia; Edwin Choy; Scott H Okuno; Mark Agulnik; Margaret von Mehren; Michael B Livingston; Vicki L Keedy; Claire F Verschraegen; Tony Philip; G Chet Bohac; Sergey Yurasov; Adam Yakovich; Hailing Lu; Michael Chen; Robert G Maki